The company’s progress follows a series of regulatory advancements, including Fast Track designation from the FDA and agreement on a pediatric study plan. These milestones are intended to accelerate the path to a future Biologics License Application. Operationally, Armata has completed four engineering runs at its in-house cGMP manufacturing facility in Los Angeles, ensuring the production capabilities necessary to support upcoming clinical trials.

Financial support for these efforts remains robust, bolstered by an additional $2.5 million in non-dilutive funding from the U.S. Department of War, bringing the total award under the current program to $28.7 million. For the second quarter of 2026, Armata reported a net income of $74.1 million, largely driven by a non-cash gain related to the fair value of its convertible loan. Excluding these accounting fluctuations, the company continues to manage research and development costs as it prepares for the Phase 3 initiation targeted for the latter half of the year. To bolster its leadership during this clinical transition, the company promoted David House to Chief Financial Officer and added Dr. Daniel B. Gilmer to its Board of Directors.